会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 61. 发明申请
    • Multithreading processor including thread scheduler based on instruction stall likelihood prediction
    • 多线程处理器,包括基于指令失速似然预测的线程调度器
    • US20060179280A1
    • 2006-08-10
    • US11051998
    • 2005-02-04
    • Michael JensenDarren JonesRyan KinterSanjay Vishin
    • Michael JensenDarren JonesRyan KinterSanjay Vishin
    • G06F9/30
    • G06F9/3851G06F9/30087G06F9/3009G06F9/382G06F9/3838G06F9/3861
    • An apparatus for scheduling dispatch of instructions among a plurality of threads being concurrently executed in a multithreading processor is provided. The apparatus includes an instruction decoder that generate register usage information for an instruction from each of the threads, a priority generator that generates a priority for each instruction based on the register usage information and state information of instructions currently executing in an execution pipeline, and selection logic that dispatches at least one instruction from at least one thread based on the priority of the instructions. The priority indicates the likelihood the instruction will execute in the execution pipeline without stalling. For example, an instruction may have a high priority if it has little or no register dependencies or its data is known to be available; or may have a low priority if it has strong register dependencies or is an uncacheable or synchronized storage space load instruction.
    • 提供了一种用于在多线程处理器中同时执行的多个线程之间调度指令调度的装置。 该装置包括:指令解码器,用于生成来自每个线程的指令的寄存器使用信息;基于寄存器使用信息和当前在执行流水线中执行的指令的状态信息生成每个指令的优先级的优先级生成器,以及选择 基于指令的优先级从至少一个线程分派至少一条指令的逻辑。 优先级表示指令在执行流水线中执行的可能性,而不会停顿。 例如,如果指令很少或没有寄存器依赖性或其数据已知可用,则指令可能具有高优先级; 或者如果具有强的寄存器依赖性或者不可缓存或同步的存储空间加载指令,则可以具有低优先级。
    • 62. 发明申请
    • Liquid, aqueous pharmaceutical composition of Factor VII polypeptides
    • 因子VII多肽的液体,水性药物组合物
    • US20060166882A1
    • 2006-07-27
    • US11304427
    • 2005-12-15
    • Michael JensenBirthe HansenTroels KornfeltKirsten Jakobsen
    • Michael JensenBirthe HansenTroels KornfeltKirsten Jakobsen
    • A61K38/36A61K33/34A61K33/26
    • A61K33/24A61K9/0019A61K33/26A61K33/32A61K33/34A61K38/4846A61K45/06A61K47/02A61K47/10A61K47/183A61K2300/00
    • The present invention is directed to liquid, aqueous pharmaceutical compositions containing Factor VII polypeptides, and methods for preparing and using such compositions, as well as vials containing such compositions, and the use of such compositions in the treatment of a Factor VII-responsive syndrome, e.g., bleeding disorders, including those caused by clotting Factor deficiencies (e.g. haemophilia A, haemophilia B, coagulation Factor VII deficiency); by thrombocytopenia or von Willebrand's disease, or by clotting Factor inhibitors, and intra cerebral haemorrhage, or excessive bleeding from any cause. The preparations may also be administered to patients in association with surgery or other trauma or to patients receiving anticoagulant therapy. More particularly, the invention relates to liquid compositions stabilised against chemical and/or physical degradation. The main embodiment is represented by a liquid, aqueous pharmaceutical composition comprising a Factor VII polypeptide (i); a buffering agent (ii) suitable for keeping pH in the range of from about 4.0 to about 9.0; at least one metal-containing agent (iii), wherein said metal is selected from the group consisting of first transition series metals of oxidation state +II, except zinc, such as chromium, manganese, iron, cobalt, nickel, and copper; and a non-ionic surfactant (iv).
    • 本发明涉及含有因子VII多肽的液体含水药物组合物,以及用于制备和使用这些组合物的方法以及含有这种组合物的小瓶,以及这些组合物在治疗因子VII应答综合征中的用途, 例如出血性疾病,包括由凝血因子缺乏引起的出血性疾病(如血友病A,血友病B,凝血因子VII缺乏症); 血小板减少症或维勒布兰氏病,或凝血因子抑制剂,脑内出血或任何原因引起的过度出血。 制剂也可以与外科手术或其他创伤相关的患者或接受抗凝治疗的患者给予。 更具体地说,本发明涉及防止化学和/或物理降解稳定的液体组合物。 主要实施方案由包含因子VII多肽(i)的液体,水性药物组合物表示; 适于将pH保持在约4.0至约9.0范围内的缓冲剂(ii); 至少一种含金属的试剂(iii),其中所述金属选自氧化态+ II的第一过渡系列金属,除了锌,如铬,锰,铁,钴,镍和铜之外; 和非离子表面活性剂(iv)。
    • 63. 发明授权
    • Keyboard and mouse support
    • 键盘和鼠标支持
    • US08740166B2
    • 2014-06-03
    • US13029727
    • 2011-02-17
    • Larry HamiltonTaiwon ChoiMichael JensenChunSheng LiDouglas CarpiauxAdam ShilenyHeidi Anna DondlingerMartin Behling, II
    • Larry HamiltonTaiwon ChoiMichael JensenChunSheng LiDouglas CarpiauxAdam ShilenyHeidi Anna DondlingerMartin Behling, II
    • A47F5/00F16M11/00
    • A47B21/0314A47B2200/0085
    • A support device including a keyboard platform and a bracket for mounting the keyboard platform a work surface to elevate the keyboard platform above the work surface. The keyboard platform is mounted on the bracket for sliding movement relative to an edge of the work surface along a horizontal fore-aft axis. The keyboard platform is mounted on the bracket for tilting movement about a tilting axis perpendicular to the fore-aft axis. The support device includes a lock movable between a locked position wherein sliding/tilting movement of the keyboard platform is prevented and an unlocked position wherein sliding/tilting movement of the keyboard platform is permitted. One aspect includes a clamp provided on the bracket and engageable with the work surface to elevate the keyboard platform above the work surface. One aspect provides a mouse platform pivotally attached to the keyboard platform and configured to support the mouse at a tilted position.
    • 包括键盘平台和支架的支撑装置,用于将键盘平台安装在工作表面上,以将键盘平台提升到工作表面上方。 键盘平台安装在支架上,用于沿着水平的前后轴线相对于工作表面的边缘滑动运动。 键盘平台安装在支架上,用于围绕垂直于前后轴线的倾斜轴线倾斜运动。 支撑装置包括可在锁定位置之间移动的锁,其中防止键盘平台的滑动/倾斜运动和允许键盘平台的滑动/倾斜运动的解锁位置。 一个方面包括设置在支架上并可与工作表面接合以提升键盘平台在工作表面上方的夹具。 一个方面提供了一种可枢转地附接到键盘平台并被配置为在倾斜位置支撑鼠标的鼠标平台。
    • 69. 发明授权
    • CE7-specific chimeric T cell receptor
    • CE7特异性嵌合T细胞受体
    • US07265209B2
    • 2007-09-04
    • US11477572
    • 2006-06-30
    • Michael Jensen
    • Michael Jensen
    • C12P21/08C07K16/00C12N5/06C12N5/08C12P21/04A61K39/395
    • C07K14/7051A61K48/00C07H21/04C07K2319/00C07K2319/02C07K2319/03C07K2319/30
    • Genetically engineered, CE7-specific redirected immune cells expressing a cell surface protein having an extracellular domain comprising a receptor which is specific for CE7, an intracellular signaling domain, and a transmembrane domain, and methods of use for such cells for cellular immunotherapy of CE7+ neuroblastoma are disclosed. In one embodiment, the immune cell is a T cell and the cell surface protein is a single chain FvFc: ζ receptor where Fv designates the VH and VL chains of a single chain monoclonal antibody to CE7 linked by peptide, Fc represents a hinge-CH2-CH3 region of a human IgG1, and ζ represents the intracellular signaling domain of the zeta chain of human CD3. DNA constructs encoding a chimeric T-cell receptor and a method of making a redirected T cell expressing a chimeric T cell receptor by electroporation using naked DNA encoding the receptor are also disclosed.
    • 基因工程化的CE7特异性重定向免疫细胞,其表达具有细胞外结构域的细胞表面蛋白,所述胞外结构域包含对CE7特异性的受体,细胞内信号结构域和跨膜结构域,以及用于此类细胞用于CE7 +神经母细胞瘤的细胞免疫治疗的方法 被披露。 在一个实施方案中,免疫细胞是T细胞,细胞表面蛋白是单链FvFc:ζ受体,其中Fv表示一个或更多个的V H链和V L链 通过肽连接的CE7单链单克隆抗体代表人IgG的铰链-CH 2 H 2 C 3 H 3区域, SUB> 1,Zeta表示人CD3的zeta链的细胞内信号转导结构域。 还公开了编码嵌合T细胞受体的DNA构建体和通过使用编码受体的裸DNA通过电穿孔制备表达嵌合T细胞受体的重定向T细胞的方法。